EPILEPSY DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)
Global epilepsy drugs market is estimated to be valued at USD 10.31 Bn in 2024 and is expected to exhibit a CAGR of 5.3% during the forecast period (2024-2031). Epilepsy is a chronic non-communicable disease characterized by recurrent seizures, which are brief episodes of involuntary movement that may involve a part of the body or the entire body. Its symptoms include abnormal electrical discharges in the brain causing seizures. It affects people of all ages but is more common in children and older adults. There is no cure for epilepsy but seizures can be controlled in about 70% of cases with medication. The global epilepsy drugs market is primarily driven by the increasing prevalence of epilepsy worldwide. Advancements in the treatment options with new drugs in the pipeline also support the growth of this market.
Market Dynamics
Global epilepsy drugs market growth is primarily driven by increasing prevalence of epilepsy worldwide. In 2022, it was estimated that over 50 million people have epilepsy globally according to the World Health Organization. The market also witnesses opportunities due to the rising healthcare expenditures across various countries. However, the market growth can be restrained by the expiry of patents of blockbuster drugs and price erosion faced by some generic drugs. The development of novel drugs for treatment-resistant epilepsy also presents growth opportunities in the market.
Key Features of the Study:
- This report provides in-depth analysis of the global epilepsy drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global epilepsy drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., Sumitomo Pharma Co., Ltd., Novartis AG, Abbott, GSK plc., Teva Pharmaceutical Industries Ltd., Sanofi, Takeda Pharmaceutical Company Limited, Marinus Pharmaceuticals, Inc, Eisai Co., Ltd, DAIICHI SANKYO COMPANY, LIMITED, Mylan N.V., Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd., Neurelis, Inc., and Supernus Pharmaceuticals, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global epilepsy drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epilepsy drugs market
Market Segmentation
Table of Contents
*Browse 32 market data tables* and 28 figures* on 'Epilepsy Drugs Market' - Global forecast to 2031
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
